Evidence map›Paper›PMID 42280273›Full record

ArticleMolecules (Basel, Switzerland)2026

Imidazole-Based AT

Florian Descamps, Marouane Rami, Jean-François Goossens, Patricia Melnyk, Maxime Liberelle, Saïd Yous

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Florian DescampsUniv. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, 59000 Lille, France.ORCID 0000-0002-5562-9397
Marouane RamiUniv. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, 59000 Lille, France.
Jean-François GoossensUniversity Lille, CHU Lille, ULR 7365 GRITA-Groupe de Recherche sur les Formes Injectables et Technologies Associées, 59000 Lille, France.ORCID 0000-0002-8551-0899
Patricia MelnykUniv. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, 59000 Lille, France.ORCID 0000-0002-9555-3446
Maxime LiberelleUniv. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, 59000 Lille, France.
Saïd YousUniv. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, 59000 Lille, France.

Funding

ministère de l'éducation et de la recherche noneUniversité de Lille none
6 · The paper itself

Abstract

The angiotensin II type 1 (AT

Indexed as

Angiotensin II Type 1 Receptor BlockersDrug DesignImidazolesReceptor, Angiotensin, Type 1AnimalsHumansLigandsLosartanMolecular Docking SimulationMolecular StructureProtein BindingReceptor, Angiotensin, Type 2Structure-Activity RelationshipAngiotensin II Type 1 Receptor BlockersImidazolesLigandsLosartanReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2angiotensin II type 1 receptorGPCR drug designimidazole-based antagonistsstructure–activity relationships

Identifiers

PMID42280273
PMCPMC13258302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.